Herbalife (NYSE:HLF) Stock, Quote.Headers.trade-ideas

Herbalife

Herbalife Nutrition

Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model. Companies' products are weight management; targeted nutrition; Energy, Sports, and Fitness; Outer Nutrition and Literature, Promotional, and Other. Weight management generates the majority of revenue from products like Meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Geographically, the main segments are North America, Mexico, South and Central America, EMEA, Asia-Pacific, and China.

Earnings

News

Health Care

Small Cap

Markets

Analyst Ratings

Trading Ideas

General

CVS Health (NYSE: CVS), the pharmacy retail and PBM powerhouse, has witnessed a substantial 24% decline over the past three months.

CVS Health Falls 24% in 3 Months: Should You Buy the Dip?

Healthcare,,Opioid,Epidemic,And,Drug,Abuse,Concept,With,The,Map

ETFs

BRBR

Advisors Series Trust VegTech Plant-based Innovation & Climate ETF

EATV

PSCC

USNA

Study shows no link between daily multivitamin use and lower risk of death in healthy adults. No difference in mortality from cancer, heart disease, or cerebrovascular diseases.

Multivitamins Show No Link To &#39;Lower Risk of Death,&#39; Study Finds

weight loss shutter2

Biotech

Equities

Large Cap

Media

DANOY

NSRGF

Nestle Sponsored representing Registered Shares Series B

NSRGY

Nestle&#39;s new Vital Pursuit brand targets individuals on weight-loss drugs without mentioning medications on packaging, addressing regulatory concerns and focusing on marketing through social media.

Nestle Carefully Targets Weight-Loss Drug Users with New Food Line

Herbalife Ltd

HONG LEONG BANK BHD by Hong Leong Bank BHD

HONG LEONG FINCL GRP ORD by Hong Leong Financial Group BHD

Hong Leong Financial Group Bhd

HALFORDS GROUP PLC ORD by Halfords Group Plc

Halfords Group PLC

HALFORDS GROUP UNSP/ADR by Halfords Group Plc

HelloFresh SE

HILTON FOOD GROUP ADR by HILTON FOOD GROUP PLC

Hilton Food Group PLC

HOME LOAN FINCL CORP by Home Loan Financial Corp.

Home Loan Financial Corp

CVS Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cvs#NYSE">CVS</a>), the pharmacy retail and PBM powerhouse, has witnessed a substantial 24% decline over the past three months. In fact, during the last trading session, the stock closed at $56.62, which marked a more than 47% plunge from its 52-week high of $83.25 and was quite close to its 52-week low of $52.77.
Not only this, the stock is currently trading below its 50-day and 200-day moving averages, indicating the possibility of a further bearish shift in the stock&#39;s price.
<h3>CVS Below 50 &amp; 200 Day SMA</h3>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/10/70629.jpg?v=964484543" style="border-style:solid; border-width:1px" />
Image Source: Zacks Investment Research
As the stock struggles to keep pace, it is now a big question for investors whether to get rid of CVS Health or grab a few more shares because the stock is hovering around its rock bottom. While the stock has been grappling with the industry-wide phenomenon of pharmacy reimbursement pressure, a turnaround might be in the cards, given its strategic initiatives that can change investors&#39; perspectives in favor of CVS Health. Let us delve deeper.
<h3>What Pulled CVS Down?</h3>
Pharmacy Reimbursement Crisis: The entire retail pharmacy industry is currently grappling with continued pressure from non-reimbursable pharmacy expenses, which are significantly pulling down mass demand for prescription as well as over-the-counter drugs and vaccinations. Going by a National Association of Chain Drugs report, payors are substantially shrinking reimbursement, many times below the cost of buying and dispensing prescription drugs. This is putting substantial and unsustainable financial pressure on the companies to the extent that many of the industry players over the past year were seen either shutting down their entire business, reducing the number of stores or going private. CVS Health, like its industry peers, is severely affected by this ongoing crisis. In fact, despite the company reporting revenue expansion, the shrinking margins and earnings are pretty alarming.
Labor Shortage Plagues the System: Despite the end of the healthcare emergency, the lingering effects forced frontline pharmacy retail workers like doctors and medical staff to leave the field. According to the article &quot;A Public Health Crisis: Staffing Shortages in Health Care,&quot; published in Favorite Healthcare Staffing, the WHO predicts a shortfall of 15 million healthcare workers worldwide in 2030. This is naturally creating huge operational hazards for companies like CVS Health, resulting in productivity loss. Going by a 2024 Boston Globe report, CVS has, in fact, acknowledged an &quot;unprecedented&quot; labor shortage among pharmacists and other staff, leading customers to complain about longer lines, unanswered phones and unclean stores.
<h3>Visible Silver Lining for CVS</h3>
<h3>2025 Roadmap Looks Impressive</h3>
CVS Health is committed to improving its Medicare Advantage margins in 2025. Given its predicted baseline performance, 2025 will be the first stage in a three to four-year journey to re-establish the company&#39;s target margins of 4 to 5%. Improved Star Ratings in 2025 might generate a $700 million tailwind, depending on membership retention levels. The remainder of the company&#39;s margin gain in 2025 will be driven by pricing initiatives in an environment where it is experiencing headwinds from an insufficient rate notice and prescription medication coverage changes that significantly raise plan liability.
CVS Health is accelerating long-term enterprise productivity measures to streamline and enhance its processes. The company&#39;s target remains to achieve low double-digit adjusted EPS growth in 2025.
<h3>Shares Outperform Industry</h3>
Over the past month, shares of CVS Health have lost 6.1%. However, the stock has outperformed the industry&#39;s 9.6% decline. While one of the company&#39;s peers, Herbalife Ltd (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hlf#NYSE">HLF</a>), registered a 2% decline, outperforming CVS, the company&#39;s prime competitor and another colossal pharmacy retail player, Walgreens Boots (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wba#NASDAQ">WBA</a>), suffered a sharper decline of 29.4% during this period due to disappointing quarterly results and further guidance cut due to unfavorable industry forecasts.
<h3>One-Month Price Comparison</h3>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/6c/70630.jpg?v=1381530106" style="border-style:solid; border-width:1px" />
Image Source: Zacks Investment Research
<h3>Upbeat Estimates</h3>
With CVS&#39; second-quarter 2024 results approaching, we expect the company to fare better than WBA. Not to forget, the company has the power to minimize its pharmacy reimbursement-related issues by adjusting its in-house PBM business strategies.
The Zacks Consensus Estimate points to revenue improvements of 3.1% and 5.5% for 2024 and 2025, respectively. However, reimbursement issues are likely to continue through the rest of 2024, creating significant bottom-line pressure for CVS Health. The Zacks Consensus Estimate indicates an earnings decline of 19.7% in 2024. However, there is some hope for investors that 2025 might get brighter, with the estimates showing a 10.6% improvement in earnings from the year-ago period.
The stock currently has a Growth Score&nbsp;of A.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/e3/70631.jpg?v=1680805760" style="border-style:solid; border-width:1px" />
Image Source: Zacks Investment Research
<h3>Waiting for a Better Entry Point Seems Prudent</h3>
As we have already discussed, the stock is currently positioned below its moving averages, which indicates potential negative movement. Further, the current earnings estimates show no visible sign of improvement until 2025.
In terms of valuation too, CVS Health&#39;s forward 12-month price-to-earnings (P/E) is 7.65X, a premium to the market&#39;s average of 7.09X. The company is also trading at a significant premium to other industry players like Walgreens Boots (4.9X) and Herbalife (6.8X). This suggests that investors may be paying a higher price relative to the company&#39;s expected earnings growth.
<h3>Premium Valuation</h3>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/fb/70632.jpg?v=1847936069" style="border-style:solid; border-width:1px" />
Image Source: Zacks Investment Research
Accordingly, despite the recent dip in share prices, this might not be the ideal time to invest in CVS Health. However, those who already own this Zacks Rank #3 (Hold) stock may stay invested as the company&#39;s financial stability and 2025 roadmap offer potential pathways to recovery.
<a href="https://www.zacks.com/stock/news/2297788/cvs-health-cvs-falls-24-in-3-months-should-you-buy-the-dip?cid=CS-BENZ-FT-analyst_blog|most_popular_stocks-2297788">To read this article on Zacks.com click here.</a>

Taking a multivitamin <a href="https://www.benzinga.com/markets/emerging-markets/23/12/36205088/inside-the-multibillion-dollar-supplement-industry-trends-and-insights">once a day</a> has long been considered a path to better health, but a new study refutes that widely held belief.
A study published in JAMA Network Open on Wednesday revealed that after tracking nearly 400,000 healthy adults for over 20 years, researchers found no link between regular multivitamin use and a lower risk of death, <a href="https://www.nih.gov/news-events/news-releases/healthy-adults-taking-multivitamins-daily-not-associated-lower-risk-death#:~:text=The%20analysis%20showed%20that%20people,heart%20disease%2C%20or%20cerebrovascular%20diseases">according </a>to the National Institutes of Health.
The study was led by researchers at the National Institutes of Health's National Cancer Institute.
Also Read: <a href="https://www.benzinga.com/markets/cannabis/23/07/33309720/healthcare-advocates-united-a-push-for-congress-to-recognize-cbd-as-dietary-supplements">Healthcare Advocates United: A Push For Congress To Recognize CBD As Dietary Supplements</a>
&#8220;The analysis showed that people who took daily multivitamins did not have a lower risk of death from any cause than people who took no multivitamins,&#8221; Erikka Loftfield, Ph.D., M.P.H., a researcher with the division of cancer epidemiology and genetics at the National Cancer Institute, wrote in the study.
&#8220;There were also no differences in mortality from cancer, heart disease, or cerebrovascular diseases. The results were adjusted for factors such as race and ethnicity, education, and diet quality.&#8221;
Loftfield also emphasized the importance of assessing the risk of death associated with multivitamin use in different populations, such as those with documented nutritional deficiencies. She highlighted the need to explore the potential impact of regular multivitamin use on aging-related health conditions.
Price Action: Despite the study&#8217;s findings on multivitamin use, related health and wellness companies saw varied market reactions. By Thursday&#8217;s afternoon trading, BellRing Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRBR#NYSE">BRBR</a>) gained 1.08% to $57.89, Herbalife Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) slipped 1.03% to $10.52, and USANA Health Sciences, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) was up 1% to $45.44.
Invesco S&amp;P SmallCap Consumer Staples ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSCC#NASDAQ">PSCC</a>) slipped 0.09% by early afternoon, while VegTech Plant-based Innovation &amp; Climate ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EATV#NYSE">EATV</a>) remained unchanged and Invesco Food &amp; Beverage ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBJ#NYSE">PBJ</a>) declined 0.68%.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/03/31554925/gianni-di-poce-rings-the-bell-on-bellring-brands-calls-for-42-returns">Gianni Di Poce Rings The Bell On BellRing Brands, Calls For 42% Returns</a></li>
</ul>
Photo: Shutterstock

Multivitamins Show No Link To 'Lower Risk of Death,' Study Finds

Last month, Nestlé SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSRGF#OTC">NSRGF</a>)&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/NSRGY#OTC">NSRGY</a>)&nbsp;unveiled&nbsp;Vital Pursuit, a new line of foods designed to complement GLP-1 weight loss medications and aid consumers&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38949073/weight-loss-drugs-like-wegvoy-and-zepbound-users-nestl-launches-5-pizza-for-you" rel="noreferrer noopener">focused on weight management</a>.&nbsp;
The European food giant said the company will not mention the weight loss drugs on the packaging.
Tom Moe, President of Meals at Nestle USA, stated that the company&#8217;s Vital Pursuit line would be marketed primarily through social media to avoid regulatory issues.
&#8220;We won&#8217;t directly make the connection (to the drugs) on the food package,&#8221; Moe emphasized in a Reuters report.
This decision highlights the regulatory uncertainties that global food companies face when targeting the growing market of people using appetite-suppressing medications, such as Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) Wegvoy and Eli Lilly And Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Zepbound.
The medications, known as GLP-1 agonists, have impacted snack-makers and fast-food chains as consumers reduce their food intake.
Reuters report adds that Nestle&#8217;s Vital Pursuit products will compete with brands that make specific claims for people who are on these medications.
For example, Biocare, a drink priced at $4.50 per serving, claims to alleviate side effects like nausea for users of semaglutide, the active ingredient in Wegovy and Ozempic.
Referencing weight-loss drugs on Vital Pursuit packaging could lead to regulatory scrutiny. &#8220;We&#8217;re not a medication, we&#8217;re a food product,&#8221; Moe noted. Mentioning medications could imply that the food treats or prevents disease, a claim only FDA-approved products can make.
The report further quoted Lauren Handel, an attorney specializing in food regulations, who advised that the safest approach is to avoid mentioning any drugs. &#8220;It&#8217;s a tricky area where you&#8217;d want to be careful about what you say,&#8221; she said, noting that labeling products as &#8220;suitable for people on a diet&#8221; may comply with regulations.
Nestle has not disclosed whether it will refer to the drugs in advertisements.
In contrast, Herbalife Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) has taken a direct approach, promoting its GLP-1 Companion Pack on Facebook to support the nutritional needs of people using GLP-1 weight-loss drugs.
Frank Lamberti, Herbalife&#8217;s Chief Commercial Officer, said the company avoids brand names like Ozempic to avoid alienating users of other drugs such as Eli Lilly&#8217;s Mounjaro and Zepbound.
Other companies, including Coca-Cola Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) and yogurt-maker Danone (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DANOY#OTC">DANOY</a>), are positioning their products as suitable for weight-loss medications due to their low sugar or high protein content. Conagra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>), maker of Healthy Choice meals, will also avoid drug names on packaging.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo via Shutterstock

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Telsey Advisory Group cut the price target for Big Lots, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIG#NYSE">BIG</a>) from $5 to $2.5. Telsey Advisory Group analyst Joseph Feldman maintained a Market Perform rating. Big Lots shares dipped 18.2% to close at $2.88 on Thursday. <a href="https://www.benzinga.com/quote/BIG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Oppenheimer raised the price target for Addus HomeCare Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADUS#NASDAQ">ADUS</a>) from $118 to $130. Oppenheimer analyst Michael Wiederhorn maintained an Outperform rating. Addus HomeCare shares rose 1.2% to close at $116.07 on Thursday. <a href="https://www.benzinga.com/quote/ADUS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer increased Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) price target from $450 to $500. Oppenheimer analyst Timothy Horan maintained an Outperform rating. Microsoft shares gained 0.1% to close at $424.52 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised the price target for NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) from $5.9 to $6. B of A Securities analyst Ming Hsun Lee maintained a Neutral rating. NIO shares fell 6.8% to close at $4.91 on Thursday. <a href="https://www.benzinga.com/quote/NIO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel cut Vail Resorts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) price target from $262 to $259. Stifel analyst Jeffrey Stantial maintained a Buy rating. Vail Resorts shares gained 0.6% to close at $193.95 on Thursday. <a href="https://www.benzinga.com/quote/MTN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho boosted Herbalife Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) price target from $10 to $11. Mizuho analyst John Baumgartner maintained a Neutral rating. Herbalife shares rose 1.7% to close at $11.43 on Thursday. <a href="https://www.benzinga.com/quote/HLF/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised the price target for 3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) from $105 to $120. B of A Securities analyst Andrew Obin upgraded the stock from Neutral to Buy. 3M shares fell 0.9% to close at $98.22 on Thursday. <a href="https://www.benzinga.com/quote/MMM/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird cut DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) price target from $65 to $55. Baird analyst William Power maintained a Neutral rating. DocuSign shares rose 2% to close at $54.60 on Thursday. <a href="https://www.benzinga.com/quote/DOCU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham slashed Ciena Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) price target from $65 to $60. Needham analyst Ryan Koontz maintained a Buy rating. Ciena shares rose 0.7% to close at $48.56 on Thursday. <a href="https://www.benzinga.com/quote/CIEN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler cut Braze, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) price target from $66 to $55. Piper Sandler analyst Brent Bracelin maintained an Overweight rating. Braze shares gained 2% to close at $36.78 on Thursday. <a href="https://www.benzinga.com/quote/BRZE/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/06/39224737/wall-streets-most-accurate-analysts-weigh-in-on-3-risk-off-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Risk Off Stocks Delivering High-Dividend Yields</a>

Price Target

ADUS

BRZE

CIEN

DOCU

MSFT

Microsoft To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday

Mizuho analyst John Baumgartner maintains Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) with a Neutral and raises the price target from $10 to $11.

Mizuho Maintains Neutral on Herbalife, Raises Price Target to $11

The earnings results for Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) for Q1 were made public on Wednesday, May 1, 2024 at 04:35 PM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Herbalife beat estimated earnings by 44.0%, reporting an EPS of $0.49 versus an estimate of $0.34.
Revenue was up $12.00 million from the same period last year.
<h3>Past Earnings Performance</h3>
The company missed on EPS by $0.11 in the last quarter, resulting in a 32.0% drop share price change the following day.
Here's a look at Herbalife's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.34</td>
<td>0.39</td>
<td>0.73</td>
<td>0.69</td>
<td>0.65</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.49</td>
<td>0.28</td>
<td>0.65</td>
<td>0.74</td>
<td>0.54</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.26B</td>
<td>1.19B</td>
<td>1.25B</td>
<td>1.28B</td>
<td>1.21B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>1.26B</td>
<td>1.22B</td>
<td>1.28B</td>
<td>1.31B</td>
<td>1.25B</td>
</tr>
</tbody>
</table>

<h3>Latest Earnings Reports from Competitors</h3>
With Herbalife's earnings data in hand, it's essential to compare its metrics to those of similar companies, including Olaplex Hldgs, Beauty Health, and Lifevantage.
<ul>
<li>Olaplex Hldgs's earnings on May 02, 2024 exceeded market projections, revealing an EPS of $0.03 compared to the estimated EPS of $0.03, resulting in a 0.0% increase.</li>
<li>Beauty Health announced strong earnings on May 09, 2024, surpassing market expectations. Despite an estimated EPS of $-0.14, Beauty Health's actual EPS was $-0.1, reflecting a 28.57% increase.</li>
<li>Lifevantage announced strong earnings on May 02, 2024, surpassing market expectations. Despite an estimated EPS of $0.16, Lifevantage's actual EPS was $0.21, reflecting a 31.25% increase.</li>
</ul>
<h3>Unpacking Competitors' Quarterly Earnings and Stock Performance</h3>
This analysis provides insights into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with the corresponding stock prices at the close of the announcement day and the open of the following trading day.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Date</th>
<th style="text-align: right;">EPS Expected</th>
<th style="text-align: right;">EPS Announced</th>
<th>EPS Change Percent</th>
<th>Stock Price At Close</th>
<th>Stock Price at Next Day Open</th>
<th>Price Change Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Herbalife</td>
<td>May 1, 2024</td>
<td style="text-align: right;">0.34</td>
<td style="text-align: right;">0.49</td>
<td>44.12%</td>
<td>$8.68</td>
<td>$9.56</td>
<td>10.14%</td>
</tr>
<tr>
<td>Olaplex Hldgs</td>
<td>May 02, 2024</td>
<td style="text-align: right;">0.03</td>
<td style="text-align: right;">0.03</td>
<td>0.0%</td>
<td>$1.64</td>
<td>$1.68</td>
<td>2.44%</td>
</tr>
<tr>
<td>Beauty Health</td>
<td>May 09, 2024</td>
<td style="text-align: right;">-0.14</td>
<td style="text-align: right;">-0.10</td>
<td>28.57%</td>
<td>$3.59</td>
<td>$3.2</td>
<td>-10.86%</td>
</tr>
<tr>
<td>Lifevantage</td>
<td>May 02, 2024</td>
<td style="text-align: right;">0.16</td>
<td style="text-align: right;">0.21</td>
<td>31.25%</td>
<td>$6.11</td>
<td>$6.06</td>
<td>-0.82%</td>
</tr>
</tbody>
</table>

<h3>Comparative Assessment: Estimated in Comparison with Actual Peer Revenues</h3>
The following table compares estimated and announced revenue figures for Herbalife's peers. This comparison provides insights into the revenue performance of these companies, offering valuable context to understand their financial standing within the industry.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Estimated Revenue</th>
<th>Announced Revenue</th>
<th>Revenue Surprise Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Herbalife</td>
<td>1.26B</td>
<td>1.26B</td>
<td>0.32%</td>
</tr>
<tr>
<td>Olaplex Hldgs</td>
<td>95.25M</td>
<td>98.91M</td>
<td>3.84%</td>
</tr>
<tr>
<td>Beauty Health</td>
<td>80.53M</td>
<td>81.40M</td>
<td>1.08%</td>
</tr>
<tr>
<td>Lifevantage</td>
<td>52.18M</td>
<td>48.24M</td>
<td>-7.54%</td>
</tr>
</tbody>
</table>

To track all earnings releases for Herbalife <a href="https://www.benzinga.com/quote/HLF/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Herbalife: Q1 Earnings Insights

Although U.S. stocks closed higher on Friday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#8217;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
Beyond
<ul>
<li>The Trade: Beyond, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) Director Joseph J Tabacco Jr <a href="https://www.benzinga.com/quote/BYON/analyst-ratings">acquired a total of 12,400 shares</a>  an average price of $16.01. To acquire these shares, it cost around $198,524.</li>
<li>What's Happening: On May 6, Beyond posted worse-than-expected first-quarter financial results..</li>
<li>What Beyond Does: Beyond Inc is an online retailer that provides products and services through websites.</li>
</ul>
<h3 class="wp-block-heading">Herbalife</h3>
<ul>
<li>The Trade: Herbalife Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) Director Juan Miguel Mendoza acquired a total of 15,000 shares at &lt;/em&gt;&lt;/a&gt; an average price of $10.55. To acquire these shares, it cost around $158,220.</li>
<li>What's Happening: On May 1, Herbalife reported better-than-expected first-quarter adjusted EPS.</li>
<li>What Herbalife Does: Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model.</li>
</ul>
Don&#8217;t forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<h3 class="wp-block-heading">MasterCraft Boat</h3>
<ul>
<li>The Trade: MasterCraft Boat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCFT#NASDAQ">MCFT</a>) 10% owner Adam Gray <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 160,330 shares</a> at an average price of $19.66. To acquire these shares, it cost around $3.19 million.</li>
<li>What's Happening: On May 8, MasterCraft Boat reported upbeat third-quarter financial results.</li>
<li>What MasterCraft Boat Does: MasterCraft Boat Holdings Inc designs, manufactures, and markets performance sport boats and outboard boats.</li>
</ul>
<h3 class="wp-block-heading">Kemper</h3>
<ul>
<li>The Trade: Kemper Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMPR#NYSE">KMPR</a>) Director Gerald Laderman <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 5,000 shares</a> at an average price of $61.01. The insider spent around $305,050 to buy those shares.</li>
<li>What's Happening: On May 1, Kemper posted weaker-than-expected quarterly earnings.</li>
<li>What Kemper Does: Kemper Corp is a diversified insurance company that provides services in property and casualty insurance, along with life and health insurance.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/05/38759538/how-to-earn-500-a-month-from-home-depot-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Home Depot Stock Ahead Of Q1 Earnings</a>

Long Ideas

Insider Trades

Pre-Market Outlook

BYON

KMPR

MCFT

Over $3M Bet On MasterCraft Boat Holdings? Check Out These 4 Stocks Insiders Are Buying

Although U.S. stocks closed higher on Monday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company&#8217;s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.
Below is a look at a few recent notable insider purchases. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Herbalife</h3>
<ul>
<li>The Trade: Herbalife Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) Director Donal L Mulligan <a href="https://www.benzinga.com/quote/HTLD/analyst-ratings">acquired a total of 45,657 shares</a> at an average price of $9.65. To acquire these shares, it cost around $289,500.</li>
<li>What's Happening: On May 1, Herbalife Nutrition reported better-than-expected first-quarter adjusted EPS.</li>
<li>What Herbalife Does: Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model.</li>
</ul>
<h3 class="wp-block-heading">Macerich</h3>
<ul>
<li>The Trade: The Macerich Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAC#NYSE">MAC</a>) President and CEO Jackson Hsieh acquired a total of 140,000 shares at an average price of $14.26. To acquire these shares, it cost around $2 million.</li>
<li>What's Happening: On April 30, Macerich posted better-than-expected first-quarter sales.</li>
<li>What Macerich Does: The Macerich Company is an S&amp;P 500 company that invests in premium mall assets.</li>
</ul>
Don&#8217;t forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a> 
<h3 class="wp-block-heading">AMREP</h3>
<ul>
<li>The Trade: AMREP Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXR#NYSE">AXR</a>) 10% owner Rainey E. Lancaster <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 10,000 shares</a> at an average price of $20.95. To acquire these shares, it cost around $209,500.</li>
<li>What's Happening: On March 8, AMREP reported earnings of 2 cents per share for its 2024 fiscal third quarter, versus year-ago earnings of $3.12 per share.</li>
<li>What AMREP Does: Amrep Corp through its subsidiaries is engaged in the Real estate business.</li>
</ul>
<h3 class="wp-block-heading">Sensata Technologies</h3>
<ul>
<li>The Trade: Sensata Technologies Holding plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) Director Ali John Mirshekari <a href="https://www.benzinga.com/sec/insider-trades/">bought a total of 268,310 shares</a> at an average price of $39.64. The insider spent around $10.64 million to buy those shares.</li>
<li>What's Happening: On April 29, Sensata Technologies reported better-than-expected first-quarter financial results.</li>
<li>What Sensata Technologies Does: Sensata Technologies is a global supplier of sensors for transportation and industrial applications.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/05/38661451/disney-electronic-arts-and-3-stocks-to-watch-heading-into-tuesday">Disney, Electronic Arts And 3 Stocks To Watch Heading Into Tuesday</a>

Over $10M Bet On Sensata Technologies? Check Out These 4 Stocks Insiders Are Buying

Watching Herbalife; Shares See A Spike In Volume On Form 4 Filed By A Co Director, Donal L Mulligan

DA Davidson analyst Linda Bolton Weiser maintains Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) with a Neutral and maintains $9.5 price target.

DA Davidson Maintains Neutral on Herbalife, Maintains $9.5 Price Target

WIIM

Herbalife Nutrition shares are trading higher after the company reported better-than-expected Q1 2024 adjusted EPS.

Herbalife Nutrition (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.35 by 40 percent. This is a 9.26 percent decrease over earnings of $0.54 per share from the same period last year. The company reported quarterly sales of $1.264 billion which met the analyst consensus estimate. This is a 0.96 percent increase over sales of $1.252 billion the same period last year.

Earnings Beats

Herbalife Nutrition Q1 2024 Adj EPS $0.49 Beats $0.35 Estimate, Sales $1.264B Inline

Herbalife Reaffirms FY24 Net Sales Growth 0-5% YoY

<h3>Gainers</h3>
<ul>
<li>Elevai Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELAB#NASDAQ">ELAB</a>) shares rose 22.7% to $0.8 during Wednesday's after-market session. The company's market cap stands at $13.8 million. </li>
<li>Vintage Wine Estates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VWE#NASDAQ">VWE</a>) shares rose 4.99% to $0.24. The market value of their outstanding shares is at $14.5 million. </li>
<li>Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) shares moved upwards by 4.52% to $9.07. The market value of their outstanding shares is at $905.3 million. As per the press release, Q1 earnings came out today. </li>
<li>Edible Garden AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDBL#NASDAQ">EDBL</a>) shares rose 4.08% to $5.1. The company's market cap stands at $1.5 million. </li>
<li>Sprouts Farmers Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) stock moved upwards by 3.81% to $66.74. The company's market cap stands at $6.7 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Top Wealth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) shares rose 3.33% to $1.24. The company's market cap stands at $35.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>The Real Good Food (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGF#NASDAQ">RGF</a>) stock fell 9.8% to $0.44 during Wednesday's after-market session. The market value of their outstanding shares is at $8.6 million. </li>
<li>Barfresh Food Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRFH#NASDAQ">BRFH</a>) shares decreased by 9.33% to $1.75. The company's market cap stands at $25.3 million. </li>
<li>Oatly Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLY#NASDAQ">OTLY</a>) stock declined by 5.13% to $1.11. The market value of their outstanding shares is at $660.5 million. The company's, Q1 earnings came out yesterday. </li>
<li>Bruush Oral Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRSH#NASDAQ">BRSH</a>) shares decreased by 3.02% to $0.06. The market value of their outstanding shares is at $6.1 million. </li>
<li>Flora Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ">FLGC</a>) stock fell 2.99% to $1.66. The company's market cap stands at $21.2 million. </li>
<li>Vector Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VGR#NYSE">VGR</a>) stock decreased by 2.68% to $10.17. The market value of their outstanding shares is at $1.6 billion. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-defensive-stocks/" title="www.benzinga.com/money/best-consumer-defensive-stocks/">www.benzinga.com/money/best-consumer-defensive-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BRFH

BRSH

EDBL

ELAB

FLGC

OTLY

Vintage Wine Estates, Inc. - Common Stock

12 Consumer Staples Stocks Moving In Wednesday's After-Market Session

U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Friday.
Shares of Ermenegildo Zegna N.V. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zgn#NYSE">ZGN</a>) fell sharply during Friday&rsquo;s session as the company reported <a href="https://www.benzinga.com/quote/ZGN/earnings">FY23 financial results.</a>
Ermenegildo Zegna reported a profit of &euro;135.7 million for FY 2023, up 107.8% year-over-year, and a profit margin of 7.1% up from 4.4% in FY 2022.
Ermenegildo Zegna shares tumbled 14% to $11.99 on Friday.
Here are some other big stocks recording losses in today&rsquo;s session.
<ul>
<li>DoubleDown Interactive Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ddi#NASDAQ">DDI</a>) fell 12.5% to $8.91.</li>
<li>Altice USA, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/atus#NYSE">ATUS</a>) shares tumbled 9.9% to $2.3169 after Wells Fargo downgraded the stock from Equal-Weight to Underweight and lowered its price target from $2 to $1.</li>
<li>MYT Netherlands Parent B.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/myte#NASDAQ">MYTE</a>) shares declined 7.7% to $3.3850.</li>
<li>Aerovate Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/avte#NASDAQ">AVTE</a>) shares dipped 7.7% to $26.85.</li>
<li>Olaplex Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/olpx#NASDAQ">OLPX</a>) fell 7.1% to $1.63. Telsey Advisory Group analyst Dana Telsey reiterated Olaplex with a Market Perform and maintained a $2 price target.</li>
<li>Critical Metals Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crml#NASDAQ">CRML</a>) fell 7% to $11.93.</li>
<li>Aurora Cannabis Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acb#NASDAQ">ACB</a>) shares fell 6.4% to $6.61.</li>
<li>Qurate Retail, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qrtea#NASDAQ">QRTEA</a>) declined 5.8% to $1.0450.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/djt#NASDAQ">DJT</a>) declined 5.5% to $43.62.</li>
<li>Herbalife Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hlf#NYSE">HLF</a>) shares fell 5.5% to $7.22. Herbalife is expected to release its first quarter 2024 financial results after the closing bell on May 1, 2024.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38110122/ethereum-falls-below-3-300-following-jobs-data-ethena-wormhole-among-top-losers"> Ethereum Falls Below $3,300 Following Jobs Data; Ethena, Wormhole Among Top Losers</a>

Penny Stocks

Intraday Update

ATUS

AVTE

CRML

MYTE

OLPX

QRTEA

Ermenegildo Zegna Reports FY23 Results, Joins Altice USA, Herbalife And Other Big Stocks Moving Lower On Friday

Herbalife Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) (the &quot;Company&quot;), a global health and wellness company, today announced that HLF Financing SaRL, LLC and Herbalife International, Inc., each a wholly owned subsidiary of the Company, intend, subject to market and other conditions, to offer&nbsp;$700 million&nbsp;aggregate principal amount of senior secured notes due 2029 (the &quot;Notes&quot;).
The Company expects to use the net proceeds from the offering to repay indebtedness, including borrowings outstanding under the Company&#39;s senior secured credit facility and a portion of the Company&#39;s&nbsp;7.875%&nbsp;Senior Notes due 2025, to pay related fees and expenses and the remainder for general corporate purposes.

Offerings

Herbalife Announces Proposed Offering of $700M Aggregate Principal Amount of Senior Secured Notes

DA Davidson analyst Linda Bolton Weiser maintains Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) with a Neutral and lowers the price target from $11 to $9.5.

DA Davidson Maintains Neutral on Herbalife, Lowers Price Target to $9.5

Herbalife Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>), a premier health and wellness company, community and platform, today announced the initiation of a refinancing process for its 2018 Term Loan B, which matures in August 2025. As of December 31, 2023,&nbsp;$650.6 million&nbsp;was outstanding under the Term Loan B. The previously announced refinancing of the Company&#39;s 2018 Term Loan A and 2018 Revolving Credit Facility is ongoing.
Overall, the Company is targeting&nbsp;$1.2 billion&nbsp;of secured financing and a&nbsp;$400 million&nbsp;revolving credit facility to repay the Term Loan A, Term Loan B and revolving credit facility, as well as a portion of the 2025 Senior Notes.

Herbalife Seeks to Refinance 2018 Loans, Targets $1.2B Secured Financing and $400M Credit Line

B of A Securities analyst Anna Lizzul maintains Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) with a Underperform and lowers the price target from $10 to $8.

B of A Securities Maintains Underperform on Herbalife, Lowers Price Target to $8

Mizuho analyst John Baumgartner maintains Herbalife (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLF#NYSE">HLF</a>) with a Neutral and lowers the price target from $12 to $10.

Mizuho Maintains Neutral on Herbalife, Lowers Price Target to $10

Tracking Seth Klarman's Baupost Group Holdings - Q1 2024 Update

Analyst Chasen Bender from Citi maintained a Buy rating on Herbalife (HLF – Research Report) and keeping the price target at $16.00. Chasen Bender ...

Herbalife's Buy Rating Backed by Positive Web and App Traffic Trends

High Liner Foods appoints Darryl Bergman as chief financial officer

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
While I tend to prefer writing about the market in the third person, the topic of fitness and the business world around it is a personal matter to me. After all, the fitness market, unlike technology or defense, relies on us, the average person, to remain relevant. For me, staying fit through gym memberships has never quite yielded the same results as spending time outdoors, and I think the reality is the <a href="https://www.bayfronthealth.com/content-hub/home-vs-gym-workouts-which-is-better/#:~:text=Exercise%20leaves%20you%20feeling%20energized,key%20to%20a%20great%20workout.">same for most of us</a>.&nbsp;



Unless you live in extreme weather conditions like the deserts of Arizona or the frozen expanses of the Rockies, getting outside and going for a walk, run or hike is likely all the exercise you need to stay healthy. Of course, weight lifting, CrossFit and other training regimens can provide benefits to your musculature, but they&rsquo;re not the end-all-be-all of fitness.&nbsp;



Unfortunately, with the pressures of social media and the ever-persistent desire to be better, the average person is at the mercy of gyms and fitness providers more than ever before. This has provided strong returns for the industries, but it has also led to the formation of a handful of stocks that are not worth holding for the long run. As such, here are three fitness stocks to sell due to their lacking prospects and value.



<h2>Peloton (PTON)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/peloton-stock-300x169.jpg" alt='An image of a grey store front with a white "Peloton" logo on the building and a smaller black sign with a white "Peloton" logo on it in front of a glass door and window.'><div>Source: Sundry Photography / Shutterstock.com</div></div>I&rsquo;ll be the first to admit that when the <a href="https://www.cnbc.com/2023/02/19/peloton-rise-fall-attempted-comeback.html">pandemic</a> made life outside less accessible, particularly in New York City, where I lived at the time, I caved and tried out Peloton (NASDAQ:<a href="https://investorplace.com/stock-quotes/pton-stock-quote/">PTON</a>) for a month. I, like many other consumers, was not impressed with the eye-watering $90 a month at the time. Moreover, the concept of <a href="https://www.cbsnews.com/news/peloton-subscription-increase-bike-price-cut/">paying monthly</a> for the bike and being able to one day own it but not be able to use it without paying the monthly membership seemed ridiculous. Thankfully, I returned it before the one-month trial period ended and saved myself a lot of dollars.



My experience and that of many others brings us to where Peloton is today, which is nothing more than a cratered stock, trying to hold onto relevance in an increasingly fitness-savvy market. The main issue for the company has been dwindling revenue resulting in an inability to turn a profit since December of 2020, at the height of the pandemic. Then a series of <a href="https://www.nbcnews.com/business/consumer/peloton-recalls-2-million-exercise-bikes-safety-hazard-rcna83932">safety recalls</a> hit its high-paying customers hard last May, causing 2 million bikes to need reinspection.



More recently, however, its answer to faltering performance has been to <a href="https://www.cnbc.com/2024/05/02/peloton-ceo-barry-mccarthy-steps-down-15percent-of-staff-laid-off.html">cut 15% of its employees</a> as its chief executive officer steps down. These kinds of moves, while good for a short-term financial adjustment, can severely impact employee morale and cause an exodus of talent.



From its financial performance to the treatment of its customers and employees, there are several reasons why Peloton should be on your list of fitness stocks to sell.



<h2>Herbalife (HLF)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/02/hlf-stock-300x169.jpg" alt="Herbalife (HLF) sign on top of a white building"><div>Source: Ken Wolter/Shutterstock.com</div></div>If a company devotes an entire webpage to explaining how it&rsquo;s not a pyramid scheme, does that mean it&rsquo;s a pyramid scheme? In the case of Herbalife (NYSE:<a href="https://investorplace.com/stock-quotes/hlf-stock-quote/">HLF</a>), such allegations have been a long-standing part of its characterization. I&rsquo;m going to assume it&rsquo;s not a pyramid scheme for the sake of argument. The bigger issue, I believe, with Herbalife is not its structure, but rather its products.



That&rsquo;s because Herbalife sustains itself from the production and sale of supplements. These products themselves are notorious for gray marketing tactics and minimal Food and Drug Administration regulation. Most Herbalife products, if not all, have <a href="https://www.herbalife.com/en-us/frequently-asked-questions/is-herbalife-fda-approved">not been evaluated by the FDA</a> to support the claims they make. 



While this is universal to the vitamin and supplement industry, one of Herbalife&rsquo;s central product lines, weight management shakes, has seen consistent year-over-year drops in sales. From 2022 to 2023, the company saw a <a href="https://ir.herbalife.com/sec-filings/all-sec-filings/content/0000950170-24-015266/0000950170-24-015266.pdf">3.5% decrease</a><div><a>EditSign</a></div> in sales of weight management shakes from $2.95 billion to $ 2.85 billion. This trend is likely to continue through 2024 as consumers become more health conscious and aware of the <a href="https://www.healthline.com/nutrition/herbalife-review#TOC_TITLE_HDR_1">unsustainable weight loss</a> provided by meal replacement shakes.



As with many other supplements and natural health solutions, Herbalife benefits from its customers misunderstanding the biochemical pathways that its products claim to interact with. Thus, it&rsquo;s not likely Herbalife has much of a future ahead of it as consumers become more wary and hold on tighter to their money.



<h2>Planet Fitness (PLNT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/plnt-stock-1-300x169.jpg" alt="A Planet Fitness (PLNT) exterior in Roseville, Minnesota."><div>Source: Ken Wolter / Shutterstock.com</div></div>The premise of Planet Fitness (NYSE:<a href="https://investorplace.com/stock-quotes/plnt-stock-quote/">PLNT</a>) is a venerable one. After all, who wouldn&rsquo;t like to go to a gym for a low price with low stakes and pressure? For much of its early history, Planet Fitness stood for the little guy &ndash; no pun intended. It created an environment in which only the most beginner-friendly fitness machines would be available. Open bench presses and squat racks were traded in for Smith machines and low-weight dumbbells.



Planet Fitness thus marketed itself as a beginner&rsquo;s gym. However, year over year for the past <a href="https://finance.yahoo.com/quote/PLNT/chart/">five years</a>, the company has struggled to provide meaningful returns to its shareholders. While this has impacted investor confidence, it could be due to the overall public perception of the company&rsquo;s gyms. For starters, a recent scandal regarding its <a href="https://www.newsweek.com/planet-fitness-boycott-stocks-market-cap-social-media-1881788">locker room management</a> sent its stock tumbling in March, which started its recent volatile trend. 



Moreover, many customers report consistently damaged and inoperable machinery with relatively <a href="https://www.consumeraffairs.com/health_clubs/planet_fitness.html">poor customer service</a>, which further damages future customer recruitment prospects. Finally, economic pressures may begin to <a href="https://www.usatoday.com/story/money/2024/05/10/planet-fitness-fee-increase/73638963007/">undercut the low-price</a> advantage that has allowed it to attract 18.7 million members. All things considered, Planet Fitness, if currently a part of your portfolio, might be best sitting in the bin of fitness stocks to sell.



On the date of publication, Viktor Zarev&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<div>Viktor Zarev is a scientist, researcher, and writer specializing in explaining the complex world of technology stocks through dedication to accuracy and understanding.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/3-sorry-fitness-stocks-to-sell-while-you-still-can/">3 Sorry Fitness Stocks to Sell While You Still Can</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Sorry Fitness Stocks to Sell While You Still Can

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Herbalife (HLF – Research Report) and Cabaletta Bio ...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Nature's Sunshine Products Stock: A Cloudy Outlook Into Second Half Of 2024

An announcement from Herbalife (HLF) is now available. Herbalife Ltd. has expanded its Board of Directors with the appointment of Perkins Miller to...

Herbalife Bolsters Board with Perkins Miller's Appointment

Herbalife Driving Sustainable Growth Through Strategic Transformation

Herbalife: Path To Sustainable Success Through Strategic Evolution

Citi analyst Chasen Bender maintained a Buy rating on Herbalife (HLF – Research Report) today and set a price target of $16.00. Chasen Bender has g...

Buy Rating Affirmed on Herbalife: Mixed Web Traffic and Strong App Engagement Signal Growth Potential

CABA

CLVT

GOOG

GOOGL

HLNFF

LBTYA

LBTYB

LBTYK

LLYVA

LLYVB

LLYVK

LSXMA

LSXMB

LSXMK

NATR

PLNT

PTON

SSNC

TBPH

TSEM

VSAT

Press Releases

Herbalife Family Foundation Celebrates 30 Years of Giving Back to Children and Families Around the World, Donating More than $50 Million Since 2005

Herbalife Activates on Mexican Olympic Committee Partnership with Nutrition and Conditioning Training at Proactive Sports in Westlake Village

Herbalife Completes $1.6 Billion Senior Secured Refinancing, Includes $1.2 Billion Senior Secured Debt and $400 Million Revolver

Two Herbalife Laboratories Earn My Green Lab Certification Bringing the Total Labs Certified to Six

Herbalife Signs LA Galaxy Midfielder Riqui Puig to Sports Nutrition Sponsorship

Herbalife Reports Year-Over-Year Net Sales Growth for Second Consecutive Quarter; Raises Full-Year 2024 Adjusted EBITDA1 Guidance

Herbalife to Participate in Water Tower Research's Consumer Products Virtual Conference on June 6

Herbalife and Herbalife Family Foundation Commit $1 Million to World Food Program USA Benefitting Women-led Agribusiness in Colombia

Herbalife Expands Board of Directors with Appointment of Perkins Miller

Herbalife to Announce Second Quarter 2024 Results on July 31

BellRing Brands

Coty

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

Estee Lauder Companies, Inc. (The) Common Stock

Estee Lauder Cos

e.l.f. Beauty

Edgewell Personal Care Company Common Stock

Edgewell Personal Care

FitLife Brands

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Honest Co

Inter Parfums

Kenvue

Lifevantage

Medifast

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Nu Skin Enterprises

Olaplex Hldgs

Safety Shot

The Beauty Health Company - Class A Common Stock

Beauty Health

United-Guardian

Unilever

Usana Health Sciences

Veru

Waldencast

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Herbalife

Herbalife (HLF) Forecast

Herbalife (NYSE:HLF) Stock, Quote.Headers.trade-ideas